DCRI fellow Dr. Paty Guimarães and Dr. Pamela Douglas discuss Dr. Douglas’s provocative study on differences in job description and compensation between male and female cardiologists.
NEAT-HFpEF randomized patients with heart failure with preserved EF to nitrates or placebo, and used accelerometer data to measure activity levels at home. Patients treated with isosorbide mononitrate had significantly lower activity levels compared to those treated with placebo, and higher doses were associated with less activity.
The highly-anticipated SPRINT trial demonstrated a 25% reduction in cardiovascular events and a 27% reduction in all-cause mortality with strict blood pressure control (SBP < 120) compared to lenient control (SBP < 140).
PROACT-4 was a pragmatic clinical trial examining in-ambulance biomarker measurement to standard care in patients with possible NTE-ACS. Measuring biomarkers in the ambulance reduced the time to disposition by 30 minutes compared to those getting standard care.
Dr. Faroukh’s group presented a patient-level meta-analysis of diabetic patients in COURAGE, BARI-2D, and FREEDOM — trials examining different options for revascularization. The meta-analysis showed that CABG was superior to PCI for reducing clinical outcomes in diabetic patients with double and triple vessel disease, even those without proximal LAD disease.
Dr. Randolph’s project demonstrated that increases in systolic blood pressure were associated with increases in mortality and heart failure hospitalizations; however, increases in diastolic blood pressure were associated with reductions in mortality.
Dr. Parikh’s study showed that heart failure patients with angina were no less functional than patients without, but they had more depressive symptoms and worse healthcare-related quality of life. In multivariate modeling, patients with angina had a higher rate of adverse cardiac outcomes.
Using the Duke echocardiogaphy databased, Dr. Vora and his collaborators compared patients with LV systolic dysfunction and severe AS that underwent TAVR to a matched cohort of patients that were medically managed. In multivariate analysis, patients undergoing TAVR had superior outcomes.
Dr. Sherwood and his collaborators looked at the TVT database, a nationwide database of patients undergoing TAVR, to identify practice patterns and outcomes in patients with atrial fibrillation undergoing TAVR.
Dr. Fuster discusses his trial examining the effect of group therapy on cardiovascular risk factor modification. Compared to individual education, group therapy produced sustained improvements in cardiovascular risk factor profile.